Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study


ANYARA Tumor Targeting Immunotherapy

ANYARA: Clinical Development

Develops Novel Treatments for Cancer and Neurodegenerative Diseases


An Experienced Team — Building Solid Partnerships


Neurodegeneration & Inflammation

Effective treatments of diseases with high medical need

Active Biotech focuses on the research and development of pharmaceuticals in therapeutic areas with high medical need, in which the immune system is of central importance. The project portfolio comprises small, orally active immunomodulatory molecules and antibody-based immunotherapy being developed for the treatment of cancer, as well as neurodegenerative diseases and inflammation.

Diseases where the immune system is of central importance